Healthcare & Medical Devices Global On demand · 24-48h

Global Glaucoma Aqueous Shunt Market Strategic Research Report

Global Glaucoma Aqueous Shunt Market Strategic Research Repo…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Glaucoma Aqueous Shunt Market
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Trabecular Meshwork-Schlemm Canal Drainage, Subconjunctival Drainage, Others

By Application: Hospital, Ophthalmology Clinics, Others

Key Players: AbbVie, Santen Pharmaceutical, Johnson and Johnson, Advanced Ophthalmic Innovations (AOI), New World Medical, Nova Eye Medical, Glaukos Corp, Alcon, iSTAR Medical, Henan Universe, Ocular Therapeutix, PolyActiva, Health Guard Biomed

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2024 · forecast to 2032
Length: 130 pages

概述

Scope of the Report

A glaucoma drainage implant is a small device placed in the eye to treat glaucoma. There are many different ways to treat glaucoma. In addition to conventional and laser surgery, there are a variety of drugs to lower intraocular pressure (IOP). If these methods alone fail, doctors may suggest implants.

It is understood that glaucoma is an irreversible blinding eye disease that is highly harmful and irreversible. Glaucoma brings heavy economic burdens and physiological and psychological distress to patients and society.

Glaucoma blindness is a chronic process. Early detection and reasonable and effective treatment can avoid blindness. Lowering intraocular pressure to treat open-angle glaucoma (POAG) is currently the only proven effective method to slow the progression of glaucoma. For every 1 mmHg decrease in intraocular pressure, the risk of glaucoma progression is reduced by 10%. The European, American and Asia-Pacific Glaucoma Associations as well as my country's glaucoma diagnosis and treatment guidelines all recommend the setting of target intraocular pressure. The main methods of treating glaucoma in my country include drugs, lasers and surgery. However, due to the complexity of risk factors, target intraocular pressures are not the same, and individuals have different responses to treatment. It has been reported that one-third of patients do not meet the target intraocular pressure, which means that they will find it difficult to maintain good vision and quality of life during their lifetime. Therefore, it is urgent to develop new methods to solve this problem. Internationally, new, minimally invasive, and biocompatible drainage devices provide more options and better solutions for glaucoma treatment.

Glaucoma aqueous shunts are implanted in the eye to establish a new aqueous humor outflow path from the anterior chamber (the area inside the eye filled with aqueous humor) to the subconjunctival space (the area between the sclera and conjunctiva). The aqueous humor is drained to the subconjunctival space through the shunt, forming a filtration bleb, thereby reducing the intraocular pressure

Market development trend

Technological innovation: With the continuous advancement of science and technology, glaucoma shunts will continue to introduce new technologies and new materials to improve product performance and safety. For example, the integration of intelligent technology will make glaucoma shunts more accurate and efficient.

Personalized treatment: With the improvement of medical level and the diversification of patient needs, personalized treatment will become an important development direction of the glaucoma shunt market. Enterprises need to provide customized products and services according to the specific conditions of patients to meet their personalized needs.

Internationalization strategy: With the development of global economic integration, the demand for glaucoma shunts in the international market is also increasing. Enterprises will strengthen international cooperation and expand overseas markets to achieve market expansion and global business layout.

This report presents a comprehensive overview of the global Glaucoma Aqueous Shunt market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Trabecular Meshwork-Schlemm Canal Drainage
  • Subconjunctival Drainage
  • Others

Segment by Application

  • Hospital
  • Ophthalmology Clinics
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Glaucoma Aqueous Shunt market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospital, Ophthalmology Clinics, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Segments covered in this report

By Type
Trabecular Meshwork-Schlemm Canal DrainageSubconjunctival DrainageOthers
By Application
HospitalOphthalmology ClinicsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Trabecular Meshwork-Schlemm Canal Drainage
  • 3.1.3 Subconjunctival Drainage
  • 3.1.4 Others
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospital
  • 4.1.3 Ophthalmology Clinics
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 AbbVie
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Santen Pharmaceutical
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Johnson and Johnson
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Advanced Ophthalmic Innovations (AOI)
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 New World Medical
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Nova Eye Medical
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Glaukos Corp
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Alcon
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 iSTAR Medical
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Henan Universe
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Ocular Therapeutix
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 PolyActiva
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Health Guard Biomed
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How is Glaucoma Aqueous Shunt defined?
It is understood that glaucoma is an irreversible blinding eye disease that is highly harmful and irreversible. Glaucoma brings heavy economic burdens and physiological and psychological distress to patients and society.
What are the main segments of the Glaucoma Aqueous Shunt market by type?
By type, the market is segmented into Trabecular Meshwork-Schlemm Canal Drainage, Subconjunctival Drainage and Others.
Which applications drive demand in the Glaucoma Aqueous Shunt market?
Key applications covered include Hospital, Ophthalmology Clinics and Others.
Who are the key players in the Glaucoma Aqueous Shunt market?
Key players profiled include AbbVie, Santen Pharmaceutical, Johnson and Johnson, Advanced Ophthalmic Innovations (AOI), New World Medical, Nova Eye Medical, Glaukos Corp and Alcon, among 13 companies covered in total.
Which regions and countries are covered for Glaucoma Aqueous Shunt?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Glaucoma Aqueous Shunt market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospital, Ophthalmology Clinics and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Glaucoma Aqueous Shunt market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.